U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07213791) titled 'A Study of LY4337713 in Participants With FAP-Positive Solid Tumors' on Oct. 07.
Brief Summary: This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
Study Start Date: Oct., 2025
...